Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCLG-APL2021 study in pediatric acute promyelocytic leukemia
ChiCTR2100052966Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tretinoin and arsenic trioxide in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoints: overall survival rate and event-free survival rate. Started Nov 2021; status: recruiting.
02
Drugs
tretinoinarsenic trioxide
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR2100052966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052966.